According to the ATS/ERS/JRS/ALAT Clinical Practice Guidelines, physiologic evidence of disease progression is defined as the presence of either of these two findings within 1 year of follow-up, if the findings are attributable to worsening fibrosis:
Absolute decline in forced vital capacity (FVC) ≥ 5%
Absolute decline in diffusing capacity for carbon dioxide (DLCO) (corrected for Hb) ≥ 10%
Although newly developed pulmonary hypertension and an acute exacerbation may be a sign of disease progression, they are highly variable and may be altered by the clinical context.
Learn more about fibrotic lung disease.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Zab Mosenifar. Fast Five Quiz: Progressive Fibrosing Interstitial Lung Disease Presentation and Diagnosis - Medscape - Apr 24, 2023.